Abstract
The bile acid-activated nuclear receptor, FXR (NR1H4), has been implicated in the control of lipid and energy metabolism, but its role in fat tissue, where it is moderately expressed, is not understood. In view of the recent development of FXR-targeting therapeutics for treatment of human metabolic diseases, understanding the tissue-specific actions of FXR is essential. Transgenic mice expressing human FXR in adipose tissue (aP2-hFXR mice) at three to five times higher levels than endogenous Fxr, i.e., much lower than its expression in liver and intestine, have markedly enlarged adipocytes and show extensive extracellular matrix remodeling. Ageing and exposure to obesogenic conditions revealed a strongly limited capacity for adipose expansion and development of fibrosis in adipose tissues of aP2-hFXR transgenic mice. This was associated with impaired lipid storage capacity, leading to elevated plasma free fatty acids and ectopic fat deposition in liver and muscle as well as whole-body insulin resistance. These studies establish that adipose FXR is a determinant of adipose tissue architecture and contributes to whole-body lipid homeostasis.
Highlights
The bile acid-activated nuclear receptor, FXR (NR1H4), has been implicated in the control of lipid and energy metabolism, but its role in fat tissue, where it is moderately expressed, is not understood
In the transgenic line used for these experiments, the total FXR mRNA expression level was increased 5.8, 3.1, and 3.2-fold in epididymal white adipose tissue (WAT) (eWAT), retroperitoneal WAT, and subcutaneous inguinal WAT, respectively, but expression was still modest when compared with expression of endogenous Fxr in liver and ileum (Fig. 1A)
FXR expression in adipose tissue leads to redistribution of body fat during high-fat diet (HFD) feeding we examined the effects of hFXR overexpression on WAT functioning in mice with a positive energy balance induced by feeding a HFD for 6 weeks (60% of calories from fat)
Summary
The bile acid-activated nuclear receptor, FXR (NR1H4), has been implicated in the control of lipid and energy metabolism, but its role in fat tissue, where it is moderately expressed, is not understood. Ageing and exposure to obesogenic conditions revealed a strongly limited capacity for adipose expansion and development of fibrosis in adipose tissues of aP2-hFXR transgenic mice This was associated with impaired lipid storage capacity, leading to elevated plasma free fatty acids and ectopic fat deposition in liver and muscle as well as wholebody insulin resistance. In view of the recent developments toward the use of FXR agonists as therapeutic agents, it is of crucial importance to have full understanding of the (patho)physiological role of FXR in specific non-enterohepatic locations, including adipose tissue This is of particular importance because obesity-associated diseases, such as type 2 diabetes and dyslipidemia, are characterized by adipose tissue dysfunction [20]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
